The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis

Nanoparticle-based drug delivery systems have considerable potential for treatment of tuberculosis (TB). The important technological advantages of nanoparticles used as drug carriers are high stability, high carrier capacity, feasibility of incorporation of both hydrophilic and hydrophobic substance...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of respiratory and critical care medicine Jg. 172; H. 12; S. 1487 - 1490
Hauptverfasser: Gelperina, Svetlana, Kisich, Kevin, Iseman, Michael D, Heifets, Leonid
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Am Thoracic Soc 15.12.2005
American Thoracic Society
Schlagworte:
Antitubercular Agents - administration & dosage
Bioavailability
Biodegradable materials
Drug Delivery Systems
Drug dosages
Humans
Nanoparticles
Nanostructures
Oral administration
Pulmonary
Tuberculosis
Tuberculosis - drug therapy
ISSN:1073-449X, 1535-4970
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Nanoparticle-based drug delivery systems have considerable potential for treatment of tuberculosis (TB). The important technological advantages of nanoparticles used as drug carriers are high stability, high carrier capacity, feasibility of incorporation of both hydrophilic and hydrophobic substances, and feasibility of variable routes of administration, including oral application and inhalation. Nanoparticles can also be designed to allow controlled (sustained) drug release from the matrix. These properties of nanoparticles enable improvement of drug bioavailability and reduction of the dosing frequency, and may resolve the problem of nonadherence to prescribed therapy, which is one of the major obstacles in the control of TB epidemics. This article highlights some of the issues of nanotechnology relevant to the anti-TB drugs.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Conflict of Interest Statement: None of the authors have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.
Originally Published in Press as DOI: 10.1164/rccm.200504-613PP on September 8, 2005
Correspondence and requests for reprints should be addressed to Leonid Heifets, M.D., Ph.D., National Jewish, 1400 Jackson Street, Denver, CO 80206. E-mail: heifetsl@njc.org
Supported by the International Science and Technology Center (Moscow, Russia), grant no. 2440, and the National Institute of Allergy and Infectious Diseases, National Institutes of Health, grant no. R21AI055284.
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.200504-613PP